CRIS Current Research Information System

PALLONI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.579
AS - Asia 3.031
EU - Europa 2.342
AF - Africa 288
SA - Sud America 135
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 9.379
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.533
SG - Singapore 1.002
CN - Cina 956
IT - Italia 645
VN - Vietnam 426
GB - Regno Unito 333
SE - Svezia 333
DE - Germania 271
HK - Hong Kong 201
KR - Corea 167
IN - India 152
NL - Olanda 129
IE - Irlanda 119
CH - Svizzera 117
CI - Costa d'Avorio 104
BR - Brasile 93
FR - Francia 84
RU - Federazione Russa 82
FI - Finlandia 77
SC - Seychelles 64
NG - Nigeria 50
TG - Togo 40
CA - Canada 27
JO - Giordania 26
ZA - Sudafrica 26
ID - Indonesia 23
AT - Austria 22
BG - Bulgaria 21
EE - Estonia 18
GR - Grecia 18
JP - Giappone 16
PL - Polonia 15
TR - Turchia 15
AR - Argentina 14
UA - Ucraina 14
MX - Messico 13
BE - Belgio 12
IQ - Iraq 10
PS - Palestinian Territory 9
EC - Ecuador 8
LT - Lituania 8
CL - Cile 6
PY - Paraguay 6
BD - Bangladesh 5
PT - Portogallo 5
ES - Italia 4
NI - Nicaragua 4
PK - Pakistan 4
AE - Emirati Arabi Uniti 3
IR - Iran 3
PE - Perù 3
RO - Romania 3
UZ - Uzbekistan 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CO - Colombia 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
HU - Ungheria 2
MA - Marocco 2
PH - Filippine 2
RS - Serbia 2
SA - Arabia Saudita 2
SI - Slovenia 2
BB - Barbados 1
CG - Congo 1
EG - Egitto 1
HT - Haiti 1
IL - Israele 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
SK - Slovacchia (Repubblica Slovacca) 1
TV - Tuvalu 1
TW - Taiwan 1
Totale 9.379
Salva come PNG Salva come JPEG
Città #
Singapore 703
Dallas 680
Ashburn 404
Hefei 396
Chandler 318
Southend 267
Fairfield 224
Hong Kong 199
Seoul 160
Bologna 127
Houston 127
Dong Ket 126
Santa Clara 120
Dublin 119
Beijing 118
Bern 107
Abidjan 104
Princeton 100
Wilmington 92
Seattle 88
Ho Chi Minh City 87
Woodbridge 86
Boardman 79
Cambridge 64
Rome 64
Hanoi 62
New York 62
Ann Arbor 57
Helsinki 57
Los Angeles 53
Frankfurt am Main 46
Lomé 40
Bengaluru 35
Milan 34
Turin 33
Berlin 32
Redmond 32
Nanjing 28
Redondo Beach 28
Amman 26
Buffalo 26
Westminster 25
Abeokuta 24
Tongling 24
Munich 22
Sofia 21
London 20
Jakarta 17
Florence 16
Lappeenranta 16
San Diego 16
Tokyo 16
Padova 14
São Paulo 14
Jinan 13
Medford 13
Nuremberg 13
Shanghai 12
Brussels 11
Hyderabad 11
Ravenna 11
Shenyang 11
Toronto 11
Brooklyn 10
Des Moines 10
Groningen 10
Olalla 10
Warsaw 10
Chicago 9
Falkenstein 9
Guangzhou 9
Halhul 9
Istanbul 9
Phoenix 9
Denver 8
Lauterbourg 8
Yubileyny 8
Zhengzhou 8
Amsterdam 7
Biên Hòa 7
Boston 7
Chennai 7
Düsseldorf 7
Haiphong 7
Montreal 7
Orem 7
Tianjin 7
Torino 7
Vienna 7
Bremen 6
Bühl 6
Council Bluffs 6
Da Nang 6
Hangzhou 6
Hebei 6
Mexico City 6
Nanchang 6
Poplar 6
Portsmouth 6
Saint Petersburg 6
Totale 6.240
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 402
Adjuvant treatment in biliary tract cancer 317
D32Left versus right side primary tumor: the correlation with clinical outcome of patients with resected stage II and III colorectal cancer 276
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 272
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES 265
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone 260
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 217
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 202
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 198
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 192
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention 189
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 184
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 182
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 179
TERC and c-MYC COPY number gain in intraductal papillary mucinous neoplasms (IPMNs): promising biomarkers of progression to malignancy 178
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 176
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 176
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 175
In Reply 171
Bone metastases in biliary cancers: A multicenter retrospective survey 171
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 171
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 170
Discovery of new potentially actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 166
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 165
TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS 165
Discovery of new potential actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 160
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 157
State of the art biological therapies in pancreatic cancer 157
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 154
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation 153
Searching for novel multimodal treatments in oligometastatic pancreatic cancer 152
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 151
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. 148
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 147
Chemotherapy in Patients with Advanced Cholangiocarcinoma 142
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 138
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 133
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 131
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 129
Radiotherapy or chemoradiation in unresectable biliary cancer: A retrospective study 128
Chemoradiation of locally advanced biliary cancer: A PRISMA-compliant systematic review 124
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 124
Decreasing Albumin mRNA Expression in Cholangiocarcinomas along the Bile Duct Tree. 121
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 119
Hacking pancreatic cancer: Present and future of personalized medicine 119
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants 114
Experimental HER2- targeted therapies for biliary tract cancer 111
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue 105
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 103
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma 99
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 97
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 97
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 97
The use of comprehensive complication Index® in pancreatic surgery: a comparison with the Clavien-Dindo system in a high volume center 94
Should we incorporate ablative radiotherapy in standard treatment of advanced intrahepatic cholangiocarcinoma? 90
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 88
Nivolumab: an investigational agent for the treatment of biliary tract cancer 86
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 85
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 83
Prognostic value of integrated morphofunctional imaging methods in inoperable intrahepatic cholangiocarcinoma 71
The use of comprehensive complication Index® in pancreatic surgery: a comparison with the Clavien-Dindo system in a high volume center 66
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 64
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab 44
Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma 30
Classic versus innovative strategies for immuno-therapy in pancreatic cancer 19
Totale 9.649
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.305
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.305
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021479 0 0 0 0 0 28 61 45 62 34 37 212
2021/20221.067 68 37 43 75 70 34 26 73 135 113 236 157
2022/20231.407 125 203 71 141 101 101 45 83 224 64 92 157
2023/2024471 76 55 32 42 37 81 20 27 15 37 28 21
2024/20251.888 100 200 163 119 169 73 114 123 61 186 173 407
2025/20263.256 530 626 992 422 475 211 0 0 0 0 0 0
Totale 9.649